Clinical and Translational Neuroscience (Feb 2023)

Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Symptom Management and Vaccination

  • Ibtisam A. Al Thubaiti,
  • Mona M. AlKhawajah,
  • Norah Al Fugham,
  • Dema A. Alissa,
  • Ahmed H. Al-Jedai,
  • Yaser M. Al Malik,
  • Mousa A. Almejally,
  • Hajer Y. Al-Mudaiheem,
  • Bedor A. Al-Omari,
  • Hessa S. AlOtaibi,
  • Rumaiza H. Al Yafeai,
  • Mohammed A. Babakkor,
  • Reem F. Bunyan,
  • Edward J. Cupler,
  • Mohammed Hakami,
  • Hanaa M. Kedah,
  • Seraj Makkawi,
  • Leena H. Saeed,
  • Jameelah A. Saeedi,
  • Eslam Shosha,
  • Mohammed A. Al Jumah

DOI
https://doi.org/10.3390/ctn7010006
Journal volume & issue
Vol. 7, no. 1
p. 6

Abstract

Read online

This article deals with recommendations on the management of symptoms of MS and on the provision of vaccinations in patients receiving disease-modifying therapies (DMTs). Symptoms of MS, such as fatigue, depression, urinary symptoms, spasticity, impairment of gait, and sexual dysfunction, are common in this population. Recognizing and addressing these symptoms is key to maintaining the quality of life of people with MS. Vaccination status should be reviewed and updated prior to initiation of DMTs. In general, vaccination should be avoided for variable periods after the initiation of some DMTs. Live attenuated vaccines are contraindicated and should be considered on a case-by-case basis. These consensus recommendations will present the best practices for vaccination in Saudi Arabia before, during, and after the COVID-19 pandemic. The recommendations will be updated periodically and as needed as new evidence becomes available.

Keywords